PL3506923T3 - Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh - Google Patents
Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hghInfo
- Publication number
- PL3506923T3 PL3506923T3 PL17846985.4T PL17846985T PL3506923T3 PL 3506923 T3 PL3506923 T3 PL 3506923T3 PL 17846985 T PL17846985 T PL 17846985T PL 3506923 T3 PL3506923 T3 PL 3506923T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical composition
- fusion protein
- growth hormone
- hormone deficiency
- hgh fusion
- Prior art date
Links
- 206010056438 Growth hormone deficiency Diseases 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160110806 | 2016-08-30 | ||
| PCT/KR2017/009471 WO2018044060A1 (en) | 2016-08-30 | 2017-08-30 | PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3506923T3 true PL3506923T3 (pl) | 2022-11-21 |
Family
ID=61726000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17846985.4T PL3506923T3 (pl) | 2016-08-30 | 2017-08-30 | Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190224281A1 (pl) |
| EP (1) | EP3506923B1 (pl) |
| JP (2) | JP7333519B2 (pl) |
| KR (2) | KR20180025269A (pl) |
| CN (2) | CN110177567A (pl) |
| BR (1) | BR112019004210A2 (pl) |
| CA (1) | CA3034240C (pl) |
| DK (1) | DK3506923T3 (pl) |
| ES (1) | ES2926627T3 (pl) |
| HU (1) | HUE059816T2 (pl) |
| JO (1) | JOP20190019A1 (pl) |
| PL (1) | PL3506923T3 (pl) |
| PT (1) | PT3506923T (pl) |
| RU (1) | RU2748402C2 (pl) |
| TW (4) | TW201924714A (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| EP4438035A1 (en) | 2021-11-26 | 2024-10-02 | Genexine, Inc. | High concentration administration formulation of hgh fusion protein |
| CN115845032A (zh) * | 2022-10-28 | 2023-03-28 | 深圳科兴药业有限公司 | 生长激素fc融合蛋白注射液及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047334A1 (en) * | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co., Ltd. | Igg fc fragment for a drug carrier and method for the preparation thereof |
| EP3173484B1 (en) * | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| US8637637B2 (en) * | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
| CA2892626A1 (en) * | 2012-12-12 | 2014-06-19 | Teva Pharmaceutical Industries Ltd. | Fusion of human growth hormone and albumin, formulation and uses thereof |
| US20160158321A1 (en) * | 2013-03-11 | 2016-06-09 | Amunix Operting Inc. | Treatment of pediatric growth hormone deficiency with human growth hormone analogues |
| DK3060239T3 (da) * | 2013-10-21 | 2020-08-03 | Opko Biologics Ltd | Langtidsvirkende polypeptider og fremgangsmåder til fremstilling og indgivelse heraf |
| HUE056849T2 (hu) * | 2014-11-21 | 2022-03-28 | Ascendis Pharma Endocrinology Div A/S | Hosszú hatástartalmú növekedési hormon adagolási formák |
| WO2017142331A1 (en) * | 2016-02-17 | 2017-08-24 | Genexine, Inc. | Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency |
-
2017
- 2017-06-16 JO JOP/2019/0019A patent/JOP20190019A1/ar unknown
- 2017-08-30 KR KR1020170110161A patent/KR20180025269A/ko not_active Application Discontinuation
- 2017-08-30 BR BR112019004210A patent/BR112019004210A2/pt unknown
- 2017-08-30 US US16/329,317 patent/US20190224281A1/en active Pending
- 2017-08-30 PT PT178469854T patent/PT3506923T/pt unknown
- 2017-08-30 TW TW108110781A patent/TW201924714A/zh unknown
- 2017-08-30 TW TW109139458A patent/TWI732713B/zh active
- 2017-08-30 CN CN201780067554.5A patent/CN110177567A/zh active Pending
- 2017-08-30 PL PL17846985.4T patent/PL3506923T3/pl unknown
- 2017-08-30 JP JP2019532910A patent/JP7333519B2/ja active Active
- 2017-08-30 DK DK17846985.4T patent/DK3506923T3/da active
- 2017-08-30 EP EP17846985.4A patent/EP3506923B1/en active Active
- 2017-08-30 TW TW106129474A patent/TWI718334B/zh active
- 2017-08-30 HU HUE17846985A patent/HUE059816T2/hu unknown
- 2017-08-30 CN CN202410025479.8A patent/CN118105512A/zh active Pending
- 2017-08-30 TW TW108110783A patent/TW201925237A/zh unknown
- 2017-08-30 RU RU2019109154A patent/RU2748402C2/ru active
- 2017-08-30 CA CA3034240A patent/CA3034240C/en active Active
- 2017-08-30 ES ES17846985T patent/ES2926627T3/es active Active
-
2018
- 2018-12-13 KR KR1020180161062A patent/KR102309668B1/ko active IP Right Grant
-
2023
- 2023-01-27 JP JP2023010975A patent/JP2023061978A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3506923B1 (en) | 2022-07-27 |
| HUE059816T2 (hu) | 2022-12-28 |
| JP7333519B2 (ja) | 2023-08-25 |
| TWI732713B (zh) | 2021-07-01 |
| KR20180136418A (ko) | 2018-12-24 |
| EP3506923A1 (en) | 2019-07-10 |
| EP3506923A4 (en) | 2020-04-22 |
| CN110177567A (zh) | 2019-08-27 |
| ES2926627T3 (es) | 2022-10-27 |
| RU2019109154A (ru) | 2020-10-01 |
| CA3034240A1 (en) | 2018-03-08 |
| JP2019533004A (ja) | 2019-11-14 |
| JOP20190019A1 (ar) | 2019-02-12 |
| TW201924714A (zh) | 2019-07-01 |
| TW201925237A (zh) | 2019-07-01 |
| RU2019109154A3 (pl) | 2020-12-30 |
| RU2748402C2 (ru) | 2021-05-25 |
| PT3506923T (pt) | 2022-09-07 |
| TWI718334B (zh) | 2021-02-11 |
| KR20180025269A (ko) | 2018-03-08 |
| JP2023061978A (ja) | 2023-05-02 |
| CN118105512A (zh) | 2024-05-31 |
| DK3506923T3 (da) | 2022-08-29 |
| KR102309668B1 (ko) | 2021-10-07 |
| TW202120119A (zh) | 2021-06-01 |
| TW201806614A (zh) | 2018-03-01 |
| US20190224281A1 (en) | 2019-07-25 |
| CA3034240C (en) | 2024-04-23 |
| BR112019004210A2 (pt) | 2019-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3298033T5 (pl) | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych | |
| HK1257375A1 (zh) | 長效fgf21融合蛋白及包含其的藥物組合物 | |
| EP3225690A4 (en) | Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use thereof | |
| HK1247933A1 (zh) | 包含bdnf的融合蛋白 | |
| HUE064504T2 (hu) | Idegi növekedési faktort tartalmazó fúziós fehérje, valamint elõállítási eljárása és alkalmazása | |
| IL262568A (en) | Inactive material based on proteins for active pharmaceutical ingredients | |
| HK1250662A1 (zh) | 用於治療癌症的免疫原性融合蛋白 | |
| PL3506923T3 (pl) | Kompozycja farmaceutyczna do leczenia niedoboru hormonu wzrostu u dzieci zawierająca białko fuzyjne hgh | |
| EP3362048A4 (en) | COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS | |
| SG11202011353XA (en) | Stable fusion protein formulation | |
| IL262875B (en) | Methods of regulation of galactosylation profiles of recombinant proteins | |
| IL283229A (en) | High concentration protein formulation | |
| HUE059593T2 (hu) | Rekombináns hGH-t tartalmazó gyógyszerkészítmény növekedési hormon hiányának kezelésére | |
| SG11202006140TA (en) | Process for providing pegylated protein composition | |
| IL289219A (en) | Composition and methods of stabilizing liquid protein formulations | |
| EP3431508A4 (en) | SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN | |
| IL249610A (en) | Chimeric proteins for cancer treatment | |
| EP3385285A4 (en) | Fusion protein for á melanocyte stimulating hormone and preparation method and use thereof | |
| SG11202005990RA (en) | Process for providing pegylated protein composition | |
| SI3731873T1 (sl) | Postopek za zagotavljanje sestavka PEGiliranih beljakovin | |
| EP3811941C0 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ILAPRAZOLE AND A SALT THEREOF AND METHOD FOR PREPARING SAME | |
| IL253218A0 (en) | A method for preparing a tnfr–fc fusion protein containing a targeted content of unpurified components | |
| EP3397644A4 (en) | Non-recombinant human insulin-like growth factor binding protein concentrate | |
| EP3173422A4 (en) | Pharmaceutical composition containing, as active ingredient, granulocyte-colony stimulating factor mutant protein or transferrin fusion protein thereof |